B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools

23Citations
Citations of this article
66Readers
Mendeley users who have this article in their library.

Abstract

B cell hyperactivity is a hallmark of the complex autoimmune disease systemic lupus erythematosus (SLE), which has justified drug development focusing on B cell altering agents during the last decades, as well as the off-label use of B cell targeting biologics. About a decade ago, the anti-B cell activating factor (BAFF) belimumab was the first biological agent to be licensed for the treatment of adult patients with active yet non-renal and non-neuropsychiatric SLE, to later be expanded to include treatment of pediatric SLE and, recently, lupus nephritis. B cell depletion is recommended as an off-label option in refractory cases, with the anti-CD20 rituximab having been the most used B cell depleting agent to date while agents with a slightly different binding specificity to CD20 such as obinutuzumab have also shown promise, forming a part of the current pipeline. In addition, terminally differentiated B cells have also been the targets of experimental therapies, with the proteasome inhibitor bortezomib being one example. Apart from being promising drug targets, B and plasma cells have also shown promise in the surveillance of patients with SLE, especially for monitoring B cell depleting or B cell altering therapies. Inadequate B cell depletion may signify poor expected clinical response to rituximab, for example, while prominent reductions in certain B cell subsets may signify a protection against flare development in patients treated with belimumab. Toward an era with a richer therapeutic armamentarium in SLE, including to a large extent B cell altering treatments, the challenge that emerges is to determine diagnostic means for evidence-based therapeutic decision-making, that uses clinical information, serological markers, and gene expression patterns to guide individualized precision strategies.

References Powered by Scopus

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

2301Citations
N/AReaders
Get full text

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial

1690Citations
N/AReaders
Get full text

2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus

1483Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Innate and Adaptive Immunity during SARS-CoV-2 Infection: Biomolecular Cellular Markers and Mechanisms

21Citations
N/AReaders
Get full text

From systemic lupus erythematosus to lupus nephritis: The evolving road to targeted therapies

18Citations
N/AReaders
Get full text

Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease

7Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Parodis, I., Gatto, M., & Sjöwall, C. (2022, August 30). B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools. Frontiers in Medicine. Frontiers Media S.A. https://doi.org/10.3389/fmed.2022.952304

Readers' Seniority

Tooltip

Researcher 13

52%

PhD / Post grad / Masters / Doc 8

32%

Professor / Associate Prof. 4

16%

Readers' Discipline

Tooltip

Medicine and Dentistry 15

54%

Immunology and Microbiology 6

21%

Biochemistry, Genetics and Molecular Bi... 4

14%

Pharmacology, Toxicology and Pharmaceut... 3

11%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 116

Save time finding and organizing research with Mendeley

Sign up for free